Metabolic Disease

Metabolic diseases – including diabetes, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and other metabolic and endocrine disorders – represent a major threat to public health, and the development of novel therapeutics for these indications is critical. By leveraging our drug discovery and development services as a metabolic disease CRO, researchers can gain critical insights into the biology underlying metabolic disease and identify promising therapeutics against these conditions.

Our non-covalent screening services have been successfully applied for the discovery and characterization of small molecules binding the GLP1 receptor (GLP1R), a key target in Type 2 Diabetes and obesity treatment. Our RapidFire screening services support high-throughput profiling of metabolites from virtually any sample type, while our proteomic services can support metabolic disease research across a range of applications. Our team is committed to advancing your metabolic disease research with high-quality data, rapid turnaround times, and deep scientific expertise through our CRO services.